Community prevalence of antibodies to SARS-CoV-2 and correlates of protective immunity in an Indian metropolitan city

This article has 1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Objectives

To assess seroprevalence of anti-SARS-CoV-2 antibodies in a densely populated urban Indian settings and its implications for disease trends and protective immunity.

Design

Cross-sectional sero-epidemiological survey linked with administrative reporting of COVID-19 testing data.

Settings

Pune city in western India

Main outcome measure

Prevalence of anti-SARS-CoV-2 spike protein antibodies were estimated and along with correlates of virus neutralisation and other immune and inflammatory markers.

Results

Seropositivity was extensive (51·3%; 95%CI 39·9 to 62·4) but varied widely in the five localities tested, ranging from 35·8% to 66·4%. Seropositivity was higher in crowded living conditions in the slums (OR 1·91), and was lower in those 65 years or older (OR 0·59). The infection-fatality ratio was estimated at 0.21%. Post survey, COVID-19 incidence was lower in areas noted to have higher seroprevalence. Substantial virus-neutralising activity was observed in seropositive individuals, but with considerable heterogeneity in the immune response and possible age-dependent diversity in the antibody repertoire.

Conclusion

Despite crowded living conditions having facilitated widespread transmission, the variability in seroprevalence in localities that are in geographical proximity indicates a heterogenous spread of infection. Declining infection rates in areas with high seropositivity suggest population-level protection. It is also supported by substantial neutralising activity in asymptomatically infected individuals. This is the first report of a significantly high proportion of protective immune response among asymptomatic individuals in the population. The heterogeneity in antibody levels and neutralisation capacity indicates the existence of immunological sub-groups of functional interest.

Trial registration

Registered with the Clinical Trials Registry of India (CTRI/2020/07/026509)

Related articles

Related articles are currently not available for this article.